Skip to content
Catalyst

PapersPMID:23325450

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

American journal of cardiovascular drugs2013The record ↗

findings
2
compound
1
endpoints
2
no difference found
1
  1. Finding, moderate evidencelowersC-reactive protein concentration
  2. Finding, moderate evidenceno difference foundInterleukin-6 concentration
Study, every finding
RCT · 3 months

What moved

How to read these marks →
  • Decreases C-reactive protein concentration

    moderate

    “IPE 4 g/day significantly decreased hsCRP levels by 36 % (p < 0.01) in MARINE and by 22 % (p < 0.001) in ANCHOR.”
    Interests
    Industry funded
    Dose studied
    icosapent ethyl (purified EPA ethyl ester) 4 g/day for 12 weeks, versus matched placebo
    Population
    Adults with hypertriglyceridemia from two phase III trials reported in one sentence: MARINE (triglycerides 500 to 2000 mg/dL) and ANCHOR (triglycerides 200 to 499 mg/dL, all on statin therapy with controlled LDL-C)

What did not

  • No detected effect on interleukin-6 concentration

    moderate

    “IPE did not cause significant changes in ICAM-1 or IL-6 levels.”
    Interests
    Industry funded
    Dose studied
    icosapent ethyl (purified EPA ethyl ester) 4 g/day and 2 g/day for 12 weeks, versus matched placebo
    Population
    Adults with hypertriglyceridemia from two phase III trials reported together: MARINE (triglycerides 500 to 2000 mg/dL) and ANCHOR (triglycerides 200 to 499 mg/dL, all on statin therapy with controlled LDL-C); both IPE doses

Study record

Design
randomised controlled trial
Species
human
Population
Hypertriglyceridemic adults: MARINE (TG 500-2000 mg/dL) and ANCHOR (TG 200-500 mg/dL on statins, high CHD risk); icosapent ethyl is purified EPA ethyl ester, no DHA
Participants
931
Comparator
placebo
Duration
84 days
Endpoints measured
36